Benchmark Reiterates Buy Rating for Humacyte (NASDAQ:HUMA)

Benchmark reiterated their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Thursday morning,Benzinga reports.

Several other brokerages have also commented on HUMA. D. Boral Capital reissued a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $15.00 price target (up from $12.00) on shares of Humacyte in a research report on Friday, December 20th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $13.71.

Humacyte Stock Performance

Humacyte stock opened at $3.37 on Thursday. The stock’s 50 day simple moving average is $4.38 and its two-hundred day simple moving average is $4.98. The stock has a market cap of $424.14 million, a price-to-earnings ratio of -2.51 and a beta of 1.30. Humacyte has a fifty-two week low of $2.81 and a fifty-two week high of $9.97.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after acquiring an additional 543,995 shares in the last quarter. State Street Corp increased its holdings in shares of Humacyte by 66.1% in the 3rd quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares in the last quarter. Woodline Partners LP increased its holdings in shares of Humacyte by 235.7% in the 4th quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock worth $14,386,000 after purchasing an additional 2,000,268 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Humacyte by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock worth $10,785,000 after purchasing an additional 94,915 shares during the last quarter. Finally, CenterBook Partners LP bought a new position in shares of Humacyte during the fourth quarter valued at $6,463,000. 44.71% of the stock is owned by hedge funds and other institutional investors.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.